Vertex Pharmaceuticals marked a 3.4% change today, compared to -0.0% for the S&P 500. Is it a good value at today's price of $311.26? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.
-
Vertex Pharmaceuticals belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) of 4.07
-
The company's P/B ratio is 6.1
-
Vertex Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of 24.0 based on its trailing 12 month price to earnings (EPS) of $12.99 per share
-
Its forward P/E ratio is 19.6, based on its forward earnings per share (EPS) of $15.85
-
VRTX has a Price to Earnings Growth (PEG) ratio of 2.2, which shows the company is overvalued when we factor growth into the price to earnings calculus.
-
Over the last four years, Vertex Pharmaceuticals has averaged free cash flows of $2,298,695,333.30, which on average grew 40.4%
-
Vertex Pharmaceuticals has moved 30.2% over the last year compared to -12.6% for the S&P 500 -- a difference of 42.9%
-
VRTX has an average analyst rating of buy and is -4.14% away from its mean target price of $324.7 per share